Creative Medical Technology Holdings Announces Next Milestone Achievements In ImmCelz Platform Development; Advancements May Result In Ability To Treat A Broader Patient Population With Immune Disorders
Portfolio Pulse from Benzinga Newsdesk
Creative Medical Technology Holdings (NASDAQ: CELZ) announced significant advances in its ImmCelz platform development, which may result in the ability to treat a broader patient population with immune disorders. The company achieved a 75% reduction in donor patient cells, greater purity, and improved functionality while reducing production costs.

May 22, 2023 | 12:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Creative Medical Technology's advances in ImmCelz platform development may lead to treating a broader patient population with immune disorders, while reducing production costs.
The advances in the ImmCelz platform development, including a 75% reduction in donor patient cells, greater purity, and improved functionality, are significant for Creative Medical Technology. These achievements may lead to the ability to treat a broader patient population with immune disorders, while reducing production costs. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100